Treatment Of Hiv-Associated Kaposi'S Sarcoma With Aldoxorubicin.

11038Background: In the past Kaposiu0027s sarcoma (KS) was a major cause of morbidity and mortality in HIV-infected individuals. Risk factors are defined by the TIS scoring system (tumor extent, immune status, symptom score, 0 or 1 each) with scores u003e / = 1 = increased risk. Current treatments for KS involve either liposomal doxorubicin(LD) or paclitaxel (P), each with up to 50% grade 3/4 AEs. Aldoxorubicin (A) is doxorubicin attached to a pH sensitive linker that binds covalently and specifically to albumin. We have treated 15 patients with KS with low dose A and monitored tumor response, adverse events and accumulation of A in the tumor and peritumor tissue. Methods: Of the 15 patients entered in the study 4 had received prior D, 1 prior LD and 1 prior P. Patients were administered either 50 mg/m2A (1), 100 mg/m2 A (7) or 150 mg/m2A (7) every 3 weeks by IV infusion. Tumor response and adverse events were recorded. Presence of KS human herpes virus (KS HHV-8; LANA+ cells) in biopsies was detected by immunofl...